XLO stock icon

Xilio Therapeutics

1.14 USD
+0.15
15.14%
Updated Nov 11, 11:53 AM EST
1 day
15.14%
5 days
-21.38%
1 month
42.32%
3 months
36.61%
6 months
1.79%
Year to date
98.26%
1 year
-19.15%
5 years
-92.88%
10 years
-92.88%
 

About: Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Employees: 73

0
Funds holding %
of 6,759 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 6

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

9% more capital invested

Capital invested by funds: $12.3M [Q1] → $13.4M (+$1.07M) [Q2]

3% more funds holding

Funds holding: 30 [Q1] → 31 (+1) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

3.21% less ownership

Funds ownership: 41.54% [Q1] → 38.33% (-3.21%) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$4
251%
upside
Avg. target
$4
251%
upside
High target
$4
251%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Raymond James
Dane Leone
75% 1-year accuracy
3 / 4 met price target
251%upside
$4
Outperform
Maintained
8 Nov 2024

Financial journalist opinion

Based on 3 articles about XLO published over the past 30 days

Charts implemented using Lightweight Charts™